Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026

Why It Matters

The data positions Retevmo as a potential new standard of care for curatively treated RET‑positive lung cancer, opening a sizable market as targeted adjuvant therapies expand.

Key Takeaways

• Selpercatinib cut recurrence risk by 83% in stage II‑IIIA NSCLC
• 24‑month EFS reached 92% with drug vs 61% on placebo
• Overall cohort showed 94% vs 70% 24‑month EFS advantage
• Median EFS not reached, indicating durable benefit
• Data published in NEJM; regulatory submissions underway

Pulse Analysis

The discovery of RET gene fusions as oncogenic drivers in a subset of non‑small cell lung cancer (NSCLC) has reshaped treatment algorithms over the past decade. While RET‑positive tumors account for roughly 1‑2% of all NSCLC cases, they often present with aggressive biology and limited options beyond chemotherapy. Selpercatinib, marketed as Retevmo, received accelerated approval in 2020 for metastatic disease, demonstrating high response rates and a favorable safety profile. Extending its use into the adjuvant setting now addresses a critical gap: preventing recurrence after curative surgery or radiotherapy.

The phase III LIBRETTO‑432 trial enrolled 151 patients with stage IB‑IIIA disease who had completed definitive local therapy. Patients received selpercatinib 160 mg twice daily or placebo, and the primary endpoint—event‑free survival (EFS)—was met with an 83% relative risk reduction in the stage II‑IIIA cohort. At 24 months, EFS was 92% versus 61% for placebo, and the overall population showed 94% versus 70%. Median EFS was not reached, suggesting a durable disease‑free interval, while overall survival trends remain immature.

The magnitude of benefit positions Retevmo as a likely new standard for adjuvant therapy in RET‑fusion NSCLC, mirroring the rapid adoption of osimertinib for EGFR‑mutated disease. Regulatory filings are expected to follow the NEJM publication, potentially unlocking a multi‑hundred‑million‑dollar market as oncologists integrate molecular testing earlier in the diagnostic pathway. Moreover, the trial underscores the broader shift toward genotype‑driven adjuvant strategies, prompting competitors to accelerate their own targeted pipelines. For investors and clinicians alike, the data signal both commercial upside and a tangible improvement in long‑term patient outcomes.